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Summary
Efflux of dopamine through the dopamine transporter
(DAT) is critical for the psychostimulatory properties
of amphetamines, but the underlying mechanism is
unclear. Here we show that Ca2+/calmodulin-depen-
dent protein kinase II (CaMKII) plays a key role in this
efflux. CaMKIIa bound to the distal C terminus of
DAT and colocalized with DAT in dopaminergic neu-
rons. CaMKIIa stimulated dopamine efflux via DAT in
response to amphetamine in heterologous cells and
in dopaminergic neurons. CaMKIIa phosphorylated
serines in the distal N terminus of DAT in vitro, and
mutation of these serines eliminated the stimulatory
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9 These authors contributed equally to this work.effects of CaMKIIa. A mutation of the DAT C terminus
impairing CaMKIIa binding also impaired amphet-
amine-induced dopamine efflux. An in vivo role for
CaMKII was supported by chronoamperometry mea-
surements showing reduced amphetamine-induced
dopamine efflux in response to the CaMKII inhibitor
KN93. Our data suggest that CaMKIIa binding to the
DAT C terminus facilitates phosphorylation of the
DAT N terminus and mediates amphetamine-induced
dopamine efflux.
Introduction
Abuse of amphetamines (AMPHs) represents a major
societal problem with more than 35 million methamphet-
amine abusers worldwide. The consequences of meth-
amphetamine use are severe and include dependence,
overdose, and death (Rawson et al., 2002). AMPHs and
other psychostimulants also can induce psychosis and
paranoia in normal subjects, and patients with schizo-
phrenia show increased sensitivity to the psychotogenic
effects of these compounds (Lieberman et al., 1997).
Nonetheless, the molecular mechanisms underlying the
effects of AMPHs on the human brain and how they might
lead to addiction are still poorly understood.
The principal target for the action of AMPHs is believed
to be the dopamine transporter (DAT), which belongs to
the solute carrier 6 (SLC6) gene family of Na+/Cl2-cou-
pled transporters that also includes the transporters for
other neurotransmitters such as norepinephrine, seroto-
nin, glycine, and GABA (Amara and Kuhar, 1993; Chen
et al., 2004; Torres et al., 2003). The DAT controls dopa-
minergic signaling by mediating rapid reuptake of dopa-
mine (DA) from the synaptic cleft. In addition to AMPHs,
other psychostimulants, including cocaine, also target
the DAT (Amara and Kuhar, 1993; Chen et al., 2004;
Torres et al., 2003). Cocaine acts as a simple inhibitor
that binds to the DAT and blocks transport activity. In
contrast, AMPHs are substrates that are actively trans-
ported (Sitte et al., 1998; Sulzer et al., 2005; Wall et al.,
1995). As substrates, AMPHs not only competitively in-
hibit DA reuptake and thereby increase synaptic DA but
also promote reversal of transport, resulting in efflux of
DA via the DAT (Sulzer et al., 2005). This efflux results in
a dramatic increase in extracellular dopamine and is be-
lieved to be of major importance for the psychostimula-
tory properties of AMPHs (Sulzer et al., 2005). The mech-
anism by which AMPHs elicit the efflux is nonetheless
unclear.
The DAT is hypothesized to function via an alternat-
ing access mechanism in which binding of substrate
together with Na+ and Cl2 triggers a conformational
change that leads to transition of the transporter from
an ‘‘outward-facing’’ conformation, in which the sub-
strate binding site is exposed to the extracellular milieu,
to an ‘‘inward-facing’’ conformation, in which the sub-
strate binding site is exposed to the intracellular milieu
(Jardetzky, 1966; Loland et al., 2003). According to this
scheme, efflux has been suggested to occur via a facili-
tated exchange mechanism, i.e., the transport of AMPH
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the inward-facing conformation and in this way increase
the likelihood that DA is transported out of the cells by
exchange (Fischer and Cho, 1979). However, increasing
evidence has challenged this model and suggested that
AMPH-induced DA efflux is not directly coupled to up-
take (Pifl and Singer, 1999; Scholze et al., 2002) and
might even involve a channel-like mode of the trans-
porter (Kahlig et al., 2005; Sitte et al., 1998). The DA efflux
induced by AMPH also appears to rely on an increase
in both intracellular sodium and calcium (Gnegy et al.,
2004; Khoshbouei et al., 2003). Moreover, we have dem-
onstrated that phosphorylation of serines in the distal N
terminus of DAT mediates the ability of AMPHs to pro-
mote DA efflux by shifting the transporter from a ‘‘reluc-
tant’’ to a ‘‘willing’’ state for efflux without interfering with
inward transport (Khoshbouei et al., 2004). Although
AMPH-induced DA efflux is regulated by certain protein
kinase C isoforms, especially the b isoform (Gnegy,
2003; Johnson et al., 2005), other kinases might also be
involved (Kantor et al., 1999; Pierce and Kalivas, 1997).
Here we provide evidence that Ca2+/calmodulin-de-
pendent protein kinase a (CaMKIIa) plays a key role in
mediating the ability of AMPH to efflux DA through
DAT. Using the C terminus of the human DAT as bait,
we identify in a yeast two-hybrid screen CaMKIIa as a
direct interaction partner of DAT. The interaction with
the DAT C terminus is confirmed in GST fusion pull-
down experiments and by coimmunoprecipitations,
and DAT is shown to colocalize with CaMKIIa in mid-
brain dopaminergic neurons. We also provide evidence
from in vitro and in vivo experiments that the association
of CaMKIIa with the DAT C terminus facilitates phos-
phorylation of N-terminal serines, which in turn supports
reversal of transport and thereby DA efflux.
Results
CaMKIIa Associates with the DAT C Terminus
In a yeast two-hybrid screen using the C terminus of the
human DAT as bait against a human brain cDNA library,
we identified a clone (clone 2-36) that encoded an in-
frame fusion with the association domain of CaMKIIa
(Figure 1A). This C-terminal domain is involved in oligo-
merization of CaMKIIa and mediates interaction with
other proteins, including densin-180 (Robison et al.,
2005; Strack et al., 2000; Walikonis et al., 2001). The inter-
action between CaMKIIa and the DAT C terminus was
validated using purified CaMKIIa autophosphorylated
with [g-32P]ATP in the presence of Ca2+ and calmodulin
(CaM). C-terminal gluthathione-S-transferase (GST) fu-
sion proteins containing either the last 46 C-terminal
residues (C46) or the last 24 residues (C24) of DAT were
capable of pulling down the 32P-labeled kinase, [32P-
Thr286]CaMKIIa (Figures 1B and 1C). In contrast, GST it-
self and a fusion protein encoding the N terminus of DAT
(amino acids 1–69) did not bind [32P-Thr286]CaMKIIa
(Figure 1D). Like C24 and C46, a C-terminal fusion encod-
ing the 40 C-terminal residues (C40) of DAT was capable
of pulling down [32P-Thr286]CaMKIIa, but deleting the 11
C-terminal residues of this fusion protein (C40del11)
markedly reduced binding (Figures 1D and 1G). In con-
trast to the results for DAT fusion proteins, a GST fusion
protein containing the last 24 residues of the homolo-gous norepinephrine transporter (NET) pulled down
CaMKIIa only very inefficiently and not to a significant
extent (Figures 1E and 1G), whereas the corresponding
serotonin transporter (SERT) GST fusion protein failed
to pull down CaMKIIa (Figures 1E and 1G).
To further explore the structural requirements for
CaMKIIa binding, we performed a series of triple-alanine
substitutions in the C24 fusion protein (Figures 1E
and 1F). Substitution to alanine of 612-614 and 615-
617 caused a marked decrease in binding of [32P-
Thr286]CaMKIIa (Figures 1E and 1F). The lack of binding
was not due to degradation or lower concentration of
the GST fusion proteins, since staining the gel for protein
revealed GST fusion protein bands of similar intensity
and size (data not shown). Regardless of their ability to
bind CaMKIIa, both 612-14 and 615-17, as well as 606-
08 and 609-11, were still capable of pulling down protein
interacting with C kinase-1 (PICK-1) (see Figure S1 in the
Supplemental Data available online), another protein
known to interact with the DAT and NET C termini (Bjerg-
gaard et al., 2004; Torres et al., 2001). We further con-
firmed the importance of the DAT C terminus for interac-
tion with CaMKIIa in GST pull-down experiments using
lysates from T-Rex HEK293 cells that expressed full-
length CaMKIIa in a tetracycline-inducible manner (T-
Rex HEK293 CaMKIIa) (Figure 2A). Pull-down experi-
ments using rat brain homogenates also showed that
the DAT C terminus can bind endogenously expressed
CaMKIIa (Figure 2B).
We assessed next whether CaMKIIa and DAT interact
in a cellular environment by coimmunoprecipitation
experiments using T-Rex HEK293 CaMKIIa cells that
were transfected with DAT. CaMKIIa was present in
immunoprecipitates obtained with an anti-DAT antibody
from DAT-transfected cells but not from nontransfected
control cells (Figure 2C). CaMKIIa also was not present
in control precipitates obtained in the absence of anti-
body (Figure 2C) or with a control antibody (data not
shown). Conversely, DAT was present in immunoprecip-
itates obtained with a CaMKIIa-specific antibody and
not in control precipitates obtained without antibody
(Figure 3B). These data demonstrate that DAT and
CaMKIIa can exist as a complex in living cells.
As a control and to demonstrate further that SERT
does not interact with CaMKIIa, we used T-Rex HEK293
CaMKIIa cells transfected with either c-myc-tagged
SERT or c-myc-tagged DAT (Figure S2). CaMKIIa was
present in the immunoprecipitates obtained with a
mouse anti-c-myc antibody from the c-myc-hDAT-
transfected cells, whereas we observed no or only a
very faint band corresponding to CaMKIIa in immuno-
precipitates from the c-myc-hSERT-transfected cells
(Figure S2). As yet another control, the CaMKIIa anti-
body did not pull down a control membrane protein
(FLAG-tagged d-opioid receptor) when it was expressed
in the cells instead of DAT (data not shown).
To assess for colocalization of CaMKIIa and DAT in
neurons, we prepared postnatal cultures of rat midbrain
dopaminergic neurons and visualized DAT by double
staining using two different DAT antibodies (MAB369,
directed against the DAT N terminus, and AB5802, di-
rected against the second extracellular loop). As ex-
pected, the staining patterns overlapped (Figure 3).
DAT immunoreactivity displayed a cluster-like pattern
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(A) Schematic view of CaMKIIa. The N-terminal kinase domain is activated by phosphorylation of Thr286, which is induced by Ca2+/calmodulin(CaM)
association with the regulatory domain (Reg). A yeast two-hybrid screen using the C-terminal 46 residues of the human DAT as bait against a human
brain cDNA library identified a clone (2–36) that was an in-frame fusion with a sequence encoding the association domain of CaMKIIa.
(B) Diagram of the hDAT topology. The C-terminal residues marked in gray are those used for the yeast two-hybrid screen. Below is a representation
of DAT, NET, and SERT GST fusion proteins used in pull-down experiments.
(C–E) Representative GST pull-down experiments of [32P]CaMKIIa comparing (C) GST with DAT C24, C46, and the N-terminal fusion protein (N); (D)
the N-terminal fusion with DAT C24, C40, and C40del11; (E) DAT C24 with the corresponding NET and SERT fusion proteins.
(F) DAT C24 with C24 containing the indicated triple Ala substitutions. In the experiments, bound [32P]CaMKIIawas detected by SDS-PAGE followed
by autoradiography of the gel.
(G) Densitometric analysis of pull-down experiments. Data are shown as binding relative to C24 (means6SE, n = 3–12, *p < 0.05, **p < 0.01, one-way
ANOVA, Dunnett’s post hoc test).along the neuronal projections in agreement with previ-
ous observations (Figure 3) (Torres et al., 2001). Most
neurons that stained for DAT (MAB369) also stained
for tyrosine hydroxylase (TH) (Figure 3), and approxi-
mately 25% of the cells could be classified as dopami-
nergic based on this dual pattern of staining (data not
shown). DAT also colocalized with the vesicular mono-
amine transporter 2 (VMAT2), a presynaptic protein
selectively expressed in monoaminergic neurons (Fig-
ure 3). Double staining for DAT and CaMKII revealed ex-
pression of CaMKII in the neurons that expressed DAT,
as well as in other neurons. In the neurons that ex-pressed both DAT and CaMKII, we observed significant
colocalization of the two proteins (Figure 3).
The N Terminus of DAT Is a Substrate for
CaMKIIa In Vitro
In rats repeatedly treated with intermittent AMPH or co-
caine, locomotor behavior and DA efflux in response to
a subsequent test dose of AMPH were increased, and
this effect was blocked by an inhibitor of CaMKII (Kantor
et al., 1999; Pierce and Kalivas, 1997). In addition, AMPH
treatment increases CaMKII activity in striatal synapto-
somes (Iwata et al., 1997). We decided accordingly to
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(A) (Upper panels) Representative (of n = 3–4) GST pull-down experiment of CaMKIIa in lysates from T-Rex HEK293 cells that expressed full-
length CaMKIIa in a tetracycline-inducible manner (T-Rex HEK293 CaMKIIa) comparing GST alone with GST hDAT C24, C40, C40del11, and
the N-terminal hDAT GST fusion protein. Bound CaMKIIa was detected by SDS-PAGE followed by immunoblotting. (Lower panels) GelCode
Blue stain of the gel showing the different GST fusions used in the pull-down experiments. The partial degradation of GST-C40 may explain
the lower intensity of the CaMKIIa band seen on the immunoblots.
(B) Representative (of n = 4) GST pull-down experiment of CaMKIIa from solubilized crude rat synaptosomes comparing GST alone with GST
hDAT C24. (Left panel) Immunoblot of SDS-PAGE with mouse anti-CaMKIIa antibody showing pull down by the hDAT C terminus but not by
GST alone. (Right panel) A GelCode Blue stain (Pierce) of the PVDF membrane showing equal loading of GST fusion proteins.
(C) CaMKIIa coimmunoprecipitates with hDAT. Immunoprecipitation was performed with MAB369 anti-DAT antibody using lysates prepared
from T-Rex HEK293 CaMKIIa cells transiently expressing DAT (T-Rex + DAT) and untransfected T-Rex HEK293 CaMKIIa (T-Rex). The immuni-
precipitates were analyzed by 10% SDS-PAGE and immunoblotted with the MAB369 anti-DAT antibody (left panel). A control with no primary
antibody (MAB369) was done in parallel (no Ab). Nonspecific antibody bands derived from MAB369 are indicated with arrows. Corresponding
samples were analyzed in parallel and immunoblotted with goat anti-CaMKIIa antibody (upper right panel). A band corresponding to the size of
CaMKIIa (w50 kDa) was only seen with the hDAT-expressing cells in the presence of MAB369 antibody. (Lower right panel) SDS-PAGE and
immunoblotting with goat anti-CaMKIIa antibody of the whole-cell lysates used for the immunoprecipitations.
(D) (Left panel) Immunoprecipitation with goat anti-CaMKIIa antibody from T-Rex HEK293 CaMKIIa cells transiently expressing hDAT (T-Rex +
DAT) and untransfected T-Rex HEK293 CaMKIIa cells (T-Rex). The immuniprecipitates were analyzed by 10% SDS-PAGE and immunoblotted
with the MAB369 anti-DAT antibody. A control with no primary antibody was done in parallel (no Ab). A band eluting corresponding to the size of
hDAT (w75 kDa) was only seen in the hDAT-expressing cells. (Right panel) SDS-PAGE and immunoblotting with MAB369 anti-DAT antibody of
the whole-cell lysates used for the immunoprecipitations. The immunoprecipitations shown are representative of three to five experiments with
similar results.investigate the involvement of CaMKII in AMPH-induced
DA efflux and to assess the functional role of CaMKII as-
sociation with the DAT C terminus. Since we recently
showed that phosphorylation of DAT N-terminal serines
is critical for AMPH-induced DA efflux (Khoshbouei
et al., 2004), we first wanted to assess whether CaMKII
could phosphorylate these serines. Notably, none of
the serines in the N terminus of DAT are within a classical
consensus sequence for any known kinase, and the N-
terminal serine(s) in DAT that is (are) phosphorylated is
unknown. We tested the ability of a series of protein
kinases to incorporate phosphate into a peptide corre-
sponding to the first 27 residues of hDAT. Phosphoryla-
tion of the N-terminal peptide was compared with that
of appropriate control substrates for each kinase (see
Experimental Procedures). The efficiency of CaMKIIa
phosphorylation of the hDAT peptide was w31% ofthat of the control substrate, autocamtide 2 (Figure 4).
In comparison, PKCa phosphorylated the peptide with
an efficiency ofw42% as compared to the control sub-
strate histone (Figure 4). In contrast, none of the other
kinases tested incorporated significant phosphate into
the N-terminal peptide (Figure 4). Thus, at least in vitro,
serines in the DAT N terminus are substrates for both
CaMKIIa and PKCa.
Activated CaMKIIa Stimulates AMPH-Induced
DAT-Mediated DA Efflux
To assess directly the role of CaMKII in AMPH-induced
DAT-mediated DA efflux, we combined amperometry
with the patch-clamp technique in the whole-cell config-
uration (Khoshbouei et al., 2004). This allowed record-
ing of DAT-mediated currents while simultaneously
measuring DA efflux by amperometry (Khoshbouei
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perfuse the intracellular environment with purified CaM-
KIIa. Addition of the activated kinase to the patch pi-
pette caused a significant increase in the voltage-
dependent AMPH-induced DA efflux (Figure 5A, left
panels) as well as in the associated whole-cell current
(Figure 5A, right panels). At +100 mV, the efflux of DA
was approximately doubled as compared to that seen
upon addition of heat-inactivated CaMKIIa to the pipette
(Figure 5A, left panels). Representative traces are shown
in the upper panels, whereas the corresponding current-
voltage relationships for the amperometric and whole
currents are shown in the lower panels of Figure 5A.
This CaMKIIa regulation did not result from changes in
the electrochemical gradient, since no change in the re-
versal potential of the AMPH-induced whole-cell current
was observed (Figure 5A, lower panels). To test whether
the stimulatory effect of CaMKIIa was dependent on
Figure 3. Colocalization of DAT and CaMKIIa in Midbrain Dopami-
nergic Neurons
The neurons were fixed in 4% paraformaldehyde, permeabilized
and stained with (upper panel) two different anti-DAT antibodies
(MAB369, directed against the DAT N terminus, and AB5802, di-
rected against the second extracellular loop), (upper middle panel)
the anti-DAT MAB369 antibody and an anti-tyrosine hydroxylase
(TH) antibody, (lower middle panel) the anti-DAT MAB369 antibody
and an anti-VMAT2 antibody, or (lower panel) the anti-DAT
MAB369 antibody and an anti-CaMKII antibody. For secondary an-
tibodies we used goat anti-rat Alexa Fluor 488 (1:1000) and goat
anti-rabbit Alexa Fluor 568 (Molecular Probes). Arrows indicate spe-
cific points of colocalization of CaMKII and DAT. Stained cells were
visualized using a Zeiss LSM 510 confocal laser scanning micro-
scope with an oil-immersion 633 objective using a 505–530 nm
bandpass filter for Alexa Fluor 488 fluorescence and 585 nm long-
pass filter for Alexa Fluor 568 fluorescence.phosphorylation of DAT N-terminal serines, we per-
formed the same experiment with two DAT mutants:
one in which Ser2, Ser4, Ser7, Ser12, and Ser13 were mu-
tated simultaneously to alanines (S/A) to prevent phos-
phorylation, and one in which the same serines were mu-
tated to aspartates to mimic their phosphorylated state
(S/D). In S/A-expressing cells, we observed w90% re-
duction in AMPH-induced DAT-mediated currents and
DA efflux, in accordance with our previous observations
(Khoshbouei et al., 2004). In addition, AMPH-induced DA
efflux by S/A was not stimulated by activated CaMKIIa in
the patch pipette (data not shown). In S/D-expressing
cells, which display AMPH-induced DA efflux similar to
wt (Khoshbouei et al., 2004), activated CaMKIIa also
failed to significantly affect DA efflux (Figure 5B, left
panels) or the whole-cell currents (Figure 5B, right
panels) at all voltages tested. This suggests that the
stimulatory effect of CaMKIIa occurs via phosphoryla-
tion of one or more the five N-terminal serines. This
phosphorylation might be mediated directly by CaMKIIa,
although an indirect role of CaMKIIa activation cannot
be ruled out.
To assess the impact of N-terminal phosphorylation
on DA efflux in the absence of AMPH, we compared
basal efflux in cells expressing the DAT S/A mutant or
the S/D mutant. Since these mutants display similar up-
take properties (Khoshbouei et al., 2004) we could as-
sume that dopamine preloading was similar in the two
cell lines. Subsequent to loading (1 mM DA for 45 min),
the cells were washed, and basal efflux was measured
by amperometry. The DAT-mediated basal DA efflux
was defined as the efflux that could be inhibited by co-
caine. As shown in Figure 4C, we observed substantially
higher basal efflux in the S/D mutant as compared to the
S/A mutant (Figure 5C); hence, N-terminal phosphoryla-
tion mimicked by the S to D substitutions was sufficient
to drive efflux in the absence of AMPH in cells with phys-
iological resting membrane potential and intracellular
sodium concentration.
Figure 4. CaMKIIa Phosphorylates the DAT N Terminus In Vitro
The relative phosphorylation efficiency of an N-terminal DAT peptide
(residues 1–27) is shown for seven different kinases as described
in Experimental Procedures. The data are expressed as phosphory-
lation relative to a standard substrate peptide (autocamtide 2 and
histone H1, for CaMKIIa and PKCa, respectively) (means 6 SD).
The experiments were performed in triplicate and repeated twice.
Under the initial rate conditions of the assay, 2.0 6 2.0, 3.5 6 3.2,
1.5 6 0.8, 3.2 6 3.2, 31.5 6 2.8, 2.6 6 0.3, and 591.3 6 100.7 nmol
phosphate per min per mg kinase were incorporated into the N-
terminal peptide by cdc2, GSK3, MEK1, P70S6K, CaMKII, PKA,
and PKCa, respectively (see Experimental Procedures and the
Supplemental Data).
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Induced Efflux of DA
(A) Application of monomeric activated
CaMKIIa via the whole-cell patch pipette
increases AMPH-induced DA efflux and cur-
rents in EM4 cells expressing wild-type YFP
DAT. Cells were voltage clamped with a patch
pipette while an amperometric electrode was
placed onto the cell membrane. The internal
solution of the patch pipette contained 2
mM DA and 30 mM Na+ (Kahlig et al., 2005).
The AMPH-induced whole-cell and ampero-
metric currents were defined as the current
recorded in the presence of AMPH minus
the current recorded after the addition of co-
caine to the bath with AMPH still present.
(Left panels) Representative trace (upper
left) and corresponding amperometric-volt-
age relationships (lower left) of AMPH-in-
duced oxidation current reflecting DA release
obtained from YFP-DAT cells upon bath ap-
plication of AMPH (10 mM) and addition of
either 0.45 mM activated (red trace or closed
symbols) or heat-inactivated (blue trace or
open symbols) monomeric CaMKIIa to the in-
ternal solution. To obtain the voltage relation-
ships, the membrane potential was stepped
from a holding potential of220 mV to voltages
between240 mV and +100 mV in 20 mV incre-
ments (means 6 SE, n = 5–8). The ampero-
metric-voltage relationships are normalized
to the current observed at +100 mV with inac-
tivated kinase (0.136 0.03 pA) and are shown
as means 6 SE, n = 5–8 (*p < 0.05, one-way
ANOVA followed by a post hoc Tukey Test).
(Right panels) Representative current trace
(upper right) and corresponding current-volt-
age relationships (lower right) of AMPH-in-
duced whole-cell current acquired concomi-
tantly to the oxidation current in the left
panels (means 6 SE, n = 5–8).
(B) Application of monomeric activated
CaMKIIa does not increase AMPH-induced
DA efflux and currents in EM4 cells expressing
YFP DAT S/D (Ser2, Ser4, Ser7, Ser12, and
Ser13 mutated to aspartates). (Left panels)
Representative trace (upper left) and corre-
sponding amperometric-voltage relationships
(lower left) of AMPH-induced oxidation current
reflecting DA release obtained from YFP-DAT
S/D cells upon bath application of AMPH (10
mM) and addition of either 0.45 mM activated
(red trace or closed symbols) or heat-inacti-
vated (blue trace or open symbols) monomeric
CaMKIIa to the internal solution. The ampero-
metric-voltage relationships are normalized
to the current observed at 100 mV with inacti-
vated kinase (0.14 6 0.04 pA) and shown as
means6 SE, n = 4. (Right panels) Representa-
tivecurrent trace (upper right)and correspond-
ing current-voltage relationships (lower right)
of AMPH-induced whole-cell current acquired
concomitantly to the oxidation current in the
left panels (means6 SE, n = 4).
(C) Basal efflux from EM4 cells expressing YFP-DAT S/D (Ser2, Ser4, Ser7, Ser12, and Ser13 mutated to aspartates) or YFP-DAT S/A (Ser2, Ser4,
Ser7, Ser12, and Ser13 mutated to alanines). Cells were preincubated with 1 mM DA for 45 min. AMPH-independent DA efflux was measured by
amperometry. DA efflux mediated by DAT was calculated by subtracting the efflux obtained in the presence of 10 mM cocaine from the efflux under
control conditions. (Left panels) Representative traces. (Right panels) DAT-mediated efflux in YFP-DAT S/D or YFP-DAT S/A calculated as
described above. Data are represented as the mean 6 SE and were compared against each other using an unpaired Student’s t test. (n = 7–10;
**p < 0.01).
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AMPH-Induced DA Efflux
(A) Effect of the CaMKII inhibitor KN93 on
AMPH-induced efflux in EM4 cells stably ex-
pressing YFP-DAT using the experimental
paradigm described in Figure 5. Data repre-
sent the DA efflux induced by 10 mM AMPH
at +80 and at +100 mV in the presence or ab-
sence of the CaMKII inhibitor KN93 (5 mM)
(means 6 SE, n = 5, *p < 0.05). No effect
was observed with the inactive analog KN92
(data not shown).
(B) The C-terminal DAT GST fusion protein
C24 but not GST alone blocked AMPH-in-
duced efflux in the YFP-DAT cells. Data rep-
resent the amperometric currents induced
by 10 mM AMPH at the indicated voltages
with addition of 3 mM GST DAT C24 or GST
to the pipette (means 6 SE, n = 5, *p < 0.05).
To obtain the voltage relationships, the mem-
brane potential was stepped from a holding
potential of 220 mV to voltages between
+20 mV and +100 mV in 20 mV increments.
(C) Effect of the CaMKII inhibitor KN93
on AMPH-induced efflux in T-Rex HEK293
CaMKIIa-FLAG hDAT cells induced with
tetracycline (TET). Cells were preloaded with
[3H]MPP+, superfused, and the experiment
was initiated with collection of 2 min frac-
tions. AMPH was added after three fractions
(6 min). (Vehicle) AMPH (3 mM) was added at
t = 6 min. (KN93) KN93 (15 mM) was added
at t = 0 min followed by AMPH (3 mM) at t = 6 min. Data are fractional release per 2 min in percent (means 6 SE of 12 observations from four
experimental days). (D) AMPH-induced efflux without (2TET) and with (+TET) induction of CaMKIIa expression with tetracycline in T-Rex
HEK293 CaMKIIa cells expressing FLAG hDAT or a mutant in which residues 612–614 were substituted with alanines (FLAG-hDAT 612–614).
AMPH (3 mM) was added at t = 0 min. Data are fractional release per 2 min in percent (means6 SE, 12 observations from four experimental days).AMPH-Induced DAT-Mediated DA Efflux Is
Facilitated by Association of CaMKIIa with
the DAT C Terminus
For intracellular perfusion with the whole-cell patch pi-
pette we were limited to the use of the monomeric form
of CaMKII, which lacks the association domain, since
full-length CaMKIIa forms a dodecameric structure that
is too large for diffusion from the pipette. Thus, the
method did not allow us to address the importance of
the binding between the association domain and the
DAT C terminus. To study the significance of the interac-
tion, we studied AMPH-induced DA efflux in DAT-ex-
pressing EM4 cells without any addition of activated
CaMKIIa. This efflux appeared to be dependent on en-
dogenously expressed CaMKIIa since it was almost
eliminated by the specific CaMKIIa inhibitor KN93 (Fig-
ure 6A). We also observed that addition to the patch
pipette of the C-terminal C24 DAT GST fusion protein
(3 mM), which would compete with the C terminus of
DAT for binding to CaMKIIa, acted as a dominant-nega-
tive regulator and eliminated AMPH-induced DA efflux
(Figure 6B). In contrast, a corresponding concentration
of GST alone maintained the AMPH-induced DA efflux
(Figure 6B).
To corroborate these electrophysiological data in a
different experimental paradigm, we studied the role of
CaMKIIa in regulating AMPH-induced radiolabeled
substrate efflux in T-Rex HEK293 CaMKIIa cells stably
expressing DAT. In these cells, tetracycline markedly up-
regulated CaMKIIa expression as assessed by immuno-
blotting, without affecting DAT function as assessed byuptake experiments (data not shown). We used a super-
fusion system that allows for continuous monitoring of
efflux after preloading cells with radioactively labeled
substrate (Pifl and Singer, 1999; Scholze et al., 2002; Sitte
et al., 1998). We used [3H]MPP+, a hydrophilic DAT sub-
strate that is resistant to enzymatic degradation and
exhibits minimal nonspecific diffusion out of the cell
(Pifl and Singer, 1999; Scholze et al., 2002; Sitte et al.,
1998). In tetracycline-induced cells, AMPH caused a
dose-dependent increase in [3H]MPP+ efflux, which
reached a maximum in the presence of 3 mM AMPH (Fig-
ure 6C and data not shown). Importantly, both the basal
and the AMPH-induced efflux of [3H]MPP+ were mark-
edly decreased by the specific CaMKIIa inhibitor KN93
(Figure 6C).
We also stably expressed in the T-Rex HEK293
CaMKIIa cells a DAT mutant in which residues 612–614
were substituted with alanines. Based on our pull-
down data, this mutation should reduce the affinity of
the DAT C terminus for CaMKIIa (Figure 1). Note that
the other DAT mutant that displayed reduced CaMKIIa
binding (DAT 615-617) (Figure 1) could not be used
because of decreased expression (Bjerggaard et al.,
2004). Basal efflux in both the wild-type and 612-614 mu-
tant cell lines was identical when CaMKIIa expression
was not induced with tetracycline (Figure 6D). However,
whereas tetracycline induction increased basal efflux in
the wild-type, we observed no effect in the 612-614 mu-
tant (Figure 6D). Furthermore, in contrast to wild-type
DAT, induction of CaMKIIa expression had no effect on
AMPH-induced efflux in the 612-614 mutant (Figure 6D).
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Induced Efflux in Midbrain Dopaminergic
Neurons
(A) Application of monomeric activated
CaMKIIa via the whole-cell patch pipette in-
creases AMPH-induced DA efflux and cur-
rents in mouse midbrain dopaminergic
neurons, using the experimental paradigm
described in Figure 5. (Left panels) Represen-
tative trace (upper left) and corresponding
amperometric-voltage relationships (lower
left) of AMPH-induced oxidation current re-
flecting DA release obtained from neurons
upon bath application of AMPH (10 mM) and
addition of either 0.225 mM activated (red
trace or closed squares) or heat-inactivated
(blue trace or closed circles) CaMKIIa to the
internal solution. To obtain the voltage rela-
tionships the membrane potential was step-
ped from a holding potential of 220 mV to
voltages between 240 mV and +100 mV in
20 mV increments (means 6 SE, n = 5–8).
The amperometric-voltage relationships are
normalized to the current observed at +100
mV with inactivated kinase (0.04 6 0.015 pA)
and shown as means 6 SE, n = 3–4 (*p <
0.05, one-way ANOVA followed by a post
hoc Tukey test). (Right panels) Representa-
tive current trace (upper right) and
corresponding current-voltage relationships
(lower right) of AMPH-induced whole-cell
current acquired concomitantly to the oxida-
tion current in the left panels (means 6 SE,
n = 3–4).
(B) Effect of the CaMKII inhibitor KN93 on
AMPH-induced efflux in mouse midbrain dopa-
minergic neurons. AMPH-induced amperomet-
ric currents (means 6 SE, n = 3–4, *p < 0.05)
recorded at +80 and at +100 mV in the pres-
ence of KN92 (5 mM) or KN93 (5 mM) were nor-
malized to vehicle controls at each potential.
(C) Basal DA efflux in dopaminergic neurons, determined by subtracting the amperometric current obtained in the presence of 10mM cocaine from
that obtained with either 0.225 mM activated or heat-inactivated CaMKIIa in the patch pipette at a membrane potential of +20 mV. Data are means
6 SE of n = 7–8 (**p < 0.01, unpaired Student’s t test).The magnitude of the AMPH-induced efflux was also
much lower (10%–20% of wt) in the mutant, regardless
of the state of induction (Figure 6D). This reduced efflux
is unlikely to be due to altered functional expression of
the mutant as [3H]DA uptake was 71% 6 2% (mean 6
SE, n = 5) of that of the wild-type in the stably transfected
pool clones.
Inhibition of CaMKIIa Reduces AMPH-Induced
DAT-Mediated DA Efflux in Midbrain DA Cultured
Neurons, Striatal Brain Slices, and in the Striatum
of Living Mice
We assessed the importance of CaMKIIa for AMPH-
induced DA efflux in a more physiological context by in-
vestigating AMPH-induced DAT-mediated DA efflux in
mouse midbrain DA neurons in culture using the amper-
ometry/whole-cell patch-clamp technique described
above. Similar to our findings in heterologous cells, acti-
vated CaMKIIa augmented significantly AMPH-induced
DA efflux (Figure 7A, left panels) as well as the parallel
whole-cell currents (Figure 7A, right panels) as com-
pared to heat-inactivated CaMKIIa. Representative
traces are shown in the upper panels, whereas the
corresponding current-voltage relationships for theamperometric and whole currents are shown in the lower
panels of Figure 7A. With the same experimental config-
uration, but without activated kinase in the pipette, the
specific CaMKII inhibitor KN93 (5 mM) essentially abol-
ished AMPH-induced DA efflux (Figure 7B). In contrast,
the inactive analog KN92 had no significant effect
(Figure 7B).
To investigate whether CaMKIIa can promote DA ef-
flux also in the absence of AMPH, and thus under
more physiological conditions, we assessed the effect
of CaMKIIa at a membrane potential of +20 mV, a poten-
tial reached during physiological neuronal stimulation.
These data showed that active, but not heat-inactivated,
CaMKIIa can stimulate efflux of DA independently from
AMPH (Figure 7C), at least under these experimental
conditions.
Further support for a critical role of CaMKII in the na-
tive setting was obtained by studying DA efflux in rat
striatal slices using the superfusion system described
above (Pifl and Singer, 1999; Scholze et al., 2002; Sitte
et al., 1998). As shown in Figure 8A, AMPH caused a pro-
found efflux of [3H]MPP+ from the preloaded slices, and
KN93 markedly inhibited this efflux. A trend toward inhi-
bition of basal efflux by KN93 was also observed.
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mouse striatum (Callaghan et al., 2005; Montanez
et al., 2003) to assess in vivo the effect of the CaMKII
inhibitor KN93 on AMPH-induced efflux of endogenous
DA. AMPH-induced DA efflux was not significantly
altered 45 and 90 min after local microinjection of vehicle
(artificial cerebral spinal fluid [aCSF]) or of KN92, the
inactive analog of KN93 (Figure 8B). In contrast, local
microinjection of KN93 significantly attenuated AMPH-
induced DA efflux (ANOVA: F2,26 = 4.31, p = 0.023). Rel-
ative to aCSF, KN93 decreased AMPH-induced DA
release by 27% at 45 min (p = 0.33, n = 9–14) and by
67% at 90 min (p < 0.05, n = 9–14) (Figure 8B). Prior to
KN93, KN92, or aCSF, AMPH induced DA release in all
mice. AMPH continued to evoke DA efflux at 90 min in
13 of 14 (93%) and 6 of 6 (100%) mice treated with
aCSF and KN-92, respectively. However, 90 min follow-
Figure 8. The CaMKII Inhibitor KN93 Decreases Efflux in Striatal
Brain Slices and in the Striatum of Living Mice
(A) The effect of the CaMKIIa inhibitor KN93 on AMPH-induced efflux
of the DAT substrate [3H]MPP+ in striatal slices. The slices were pre-
loaded with [3H]MPP+, superfused, and 2 min fractions were
collected. (Vehicle) AMPH (3 mM) was added at t = 6 min; (KN93)
KN93 (15 mM) was added at t = 0 min followed by AMPH (3 mM) at
t = 6 min. Data are fractional release per 2 min in percent (means 6
SE, 12 observations, one observation equals one superfusion
chamber).
(B) The effect of KN93 on DA efflux induced by locally applied AMPH
in the striatum of anesthetized mice as assessed by in vivo high-
speed chronoamperometry. Data are presented as fractional
AMPH-induced DA efflux after locally applied vehicle (aCSF) (open
circles), KN92 (open triangles), or KN93 (closed circles) relative to
the pretreatment AMPH-induced DA efflux (means 6 SE, *p < 0.05
versus vehicle). Pretreatment values were 0.81 6 0.13 micromolar
DA (n = 14), 0.926 0.22 micromolar DA (n = 6), and 0.896 0.23 micro-
molar DA (n = 9) for vehicle (aCSF), KN92, and KN93 treated mice,
respectively.ing KN93, AMPH-evoked DA efflux was only detected in
4 of 9 mice (56%).
Discussion
Like other Na+-coupled transporters, DAT is capable not
only of mediating Na+-coupled uptake but also of trans-
porting substrate in the reverse direction. The reverse
transport, or efflux, of DA through DAT seen in response
to AMPHs is believed to play a significant role in the ad-
dictive and reinforcing properties of these compounds
(Sulzer et al., 2005). Recently, we discovered that phos-
phorylation of N-terminal serines mediates the reversal
of transport in response to AMPHs (Khoshbouei et al.,
2004). Thus, N-terminal phosphorylation shifts DAT
from a ‘‘reluctant’’ to a ‘‘willing’’ state for AMPH-induced
efflux (Khoshbouei et al., 2004). Consistent with this hy-
pothesis, AMPH and methamphetamine increase phos-
phorylation of DAT both in vivo and in vitro (Cervinski
et al., 2005), and truncation of the distal 21 N-terminal
residues in DAT prevent this phosphorylation (Cervinski
et al., 2005), in agreement with AMPH-induced phos-
phorylation of N-terminal serines.
In the present paper we identify CaMKII as key player
in AMPH-induced DA efflux. We provide data supporting
an interaction of the CaMKIIa association domain with
the C terminus of DAT, which might operate to increase
the likelihood that the kinase domain will phosphorylate
serines in the N terminus and thus promote AMPH-in-
duced DA efflux. First, in a yeast two-hybrid screen we
identified CaMKIIa as a putative interaction partner for
the DAT C terminus. Second, we confirmed and mapped
the interaction to discrete residues in the distal C termi-
nus using pull-down and coimmunoprecipitation exper-
iments. Third, we confirmed that CaMKIIa and DAT are
coexpressed and colocalize in dopaminergic neurons
in primary culture. Fourth, we demonstrated that CaMKII
can phosphorylate in vitro a synthetic DAT N-terminal
peptide. Fifth, by using an array of different techniques
in heterologous cells, dopaminergic neurons, striatal
brain slices, and living animals, we demonstrated a
key role for CaMKIIa in AMPH-induced DA efflux. Fi-
nally, we obtained evidence that binding of the kinase
to the DAT C terminus is an important element in the
pathway by using a C-terminal DAT GST fusion protein
(C24) to decrease CaMKIIa binding to DAT or by using
a mutant DAT with impaired ability to bind CaMKIIa.
Although in the whole-cell patch-clamp/amperometry
setup, addition of activated monomeric CaMKIIa lacking
the association domain still stimulated efflux, this likely
results because the concentration of the activated ki-
nase at the plasma membrane, when added with the
patch pipette, is sufficient to substitute for the lack of
its interaction with the C terminus of DAT.
It is conceivable that our proposed role for CaMKIIa to
mediate DA efflux in response to AMPH also is important
under physiological conditions. Indeed, DAT has been
proposed to play a role in nonvesicular release of DA
in the substantia nigra upon excitation of glutamater-
gic neurons projecting from the subthalamic nucleus
through a mechanism involving membrane depolariza-
tion and changes in the ionic gradient (Falkenburger
et al., 2001). Consistent with this possibility, we demon-
strated that activated CaMKIIa, which would result from
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2003; Griffith, 2004), can stimulate DA efflux in dopami-
nergic neurons in the absence of AMPH at +20 mV, a po-
tential reached during physiological neuronal stimula-
tion (Figure 7C). We should note that in the absence of
AMPH, 2 mM is a high intracellular DA concentration;
however, we have shown previously that the properties
of DA efflux at this concentration are similar to those ob-
tained at much lower intracellular DA concentrations
(Kahlig et al., 2005). To obtain a sufficient signal-to-noise
ratio in DA neurons, which have very small amperometric
currents, we therefore used this high intracellular DA
concentration. The experiments were also performed
in the presence of a relatively high concentration of intra-
cellular sodium (30 mM). However, intracellular sodium
can rise appreciably during neuronal activity: for exam-
ple, a tetanic stimulus that is typically used to trigger
long-term potentiation has been shown to increase the
intracellular sodium concentration to as much as 45
mM within the shafts of dendrites and to over 100 mM
in active dendritic spines (Rose and Konnerth, 2001).
Moreover, recovery to baseline sodium levels, which is
mediated by the plasma membrane Na+/K+-ATPase, is
very slow, typically requiring tens of seconds (Rose,
2002).
Our data obtained in cells preloaded with [3H]MPP
provided further support for the notion that efflux
through DAT can occur in a CaMKIIa-dependent manner
without AMPH, since KN93 potently inhibited basal ef-
flux of [3H]MPP preloaded cells expressing the hDAT
(Figure 6C). In addition, induction of CaMKII expression
enhanced basal efflux of [3H]MPP+ in the wild-type but
not in cells expressing a transporter with impaired
CaMKII binding (Figure 6D). We also show that pseudo-
phosphorylation of the hDAT N-terminal serines (S/D
mutation), which appear to be phosphorylated by
CaMKIIa, causes reverse transport of DA at resting
membrane potential in unclamped cells, thereby mim-
icking what could happen upon CaMKII activation in
the absence of amphetamine (Figure 5C).
An interesting question is how N-terminal phosphory-
lation mechanistically is coupled to stimulation of DA ef-
flux. We have shown previously that pseudophosphory-
lation of the DAT N terminus (S/D mutant) does not affect
the rate of substrate accumulation of substrate in un-
clamped cells (Khoshbouei et al., 2004). Therefore, at
least in unclamped cells, N-terminal phosphorylation al-
ters the rate of efflux without altering the reuptake of DA.
Nevertheless, despite that the rate of uptake appears to
be unaltered in the mutant, it is possible that phosphor-
ylation might alter the ionic coupling of DAT. The ratio of
whole-cell to amperometric current was, however, not
altered by preventing phosphorylation (Khoshbouei
et al., 2004). This ratio is a microscopic property of an
individual transporter that is inversely proportional to
the fraction of charge carried by substrate (Galli et al.,
1997). The data are consistent, therefore, with a similar
ionic coupling in the presence or absence of N-terminal
phosphorylation.
Earlier studies indicated a role of CaMKII in AMPH-in-
duced efflux, but only after psychostimulant sensitiza-
tion (Kantor et al., 1999; Pierce and Kalivas, 1997),
whereas we have demonstrated a role for CaMKII in the
acute response to AMPH. Most likely this results fromdifferences in the experimental approaches: Kantor
et al. used substantially larger striatal slices and a slower
perfusion (Kantor et al., 1999), and for the in vivo experi-
ments we used high-speed chronoamperometry, which
has a high time resolution, instead of microdialysis
(Kantor et al., 1999; Pierce and Kalivas, 1997). Previous
studies have also suggested involvement of PKC in
AMPH-induced efflux. Measurements in striatal slices
and microdialysis experiments in nucleus accumbens
showed that AMPH-induced DA efflux in naive and in be-
haviorally sensitized animals was decreased by PKC in-
hibitors (Kantor et al., 1999; Pierce and Kalivas, 1997).
Additionally, the increase in phosphorylation of N-termi-
nal serines in DAT seen in response to AMPHs is de-
creased by a high concentration of the PKC inhibitor
GF109230X (Cervinski et al., 2005) and phosphorylation
of the N-terminal serines is promoted by PKC activators
such as PMA (Granas et al., 2003). Recent data have
moreover suggested a particular role of the PKCb iso-
form (Johnson et al., 2005). The present data also do
not exclude a role of PKC. In fact, we show that the
DAT N terminus is a substrate for PKCa, at least in vitro,
and the PKC inhibitor GF109230X inhibited AMPH-
induced efflux of [3H]MPP+ from striatal slices to a similar
extent as KN93 (data not shown). In contrast, the effect
of the PKC inhibitor was markedly smaller than that of
KN93 in cells cotransfected with DAT and CaMKIIa
(data not shown), and we observed no effect of
GF109230X (1 mM) on the increase in DA efflux observed
when autoactivated CaMKIIawas added to the patch pi-
pette (data not shown). Thus, although interplay between
PKC and CaMKIIa is possible, our data suggest that
CaMKII mediation of AMPH-induced DA efflux is inde-
pendent of PKC.
CaMKII is the most abundant kinase in the brain and
plays major roles in regulation of complex cognitive
and behavioral functions, including synaptic plasticity
(Colbran, 2003; Griffith, 2004). Activation of the kinase
occurs upon local increases in Ca2+ concentration and
involves binding of the Ca2+/calmodulin complex to
the regulatory domain (Colbran, 2003; Griffith, 2004).
CaMKII is well known to interact with several proteins
important for neuronal signal transduction. Most pro-
teins, including the NR2B subunit of the NMDA receptor
and a-actinin bind the catalytic or regulatory domain
(Colbran, 2003; Griffith, 2004). In contrast, densin-180
interacts with the C-terminal association domain that
also is known to be involved in oligomerization of the
enzyme (Robison et al., 2005). Functionally, the interac-
tion with densin-180 is believed to play a significant role
in determining the subcellular localization of CaMKIIa,
with little effect on catalytic activity (Robison et al.,
2005). The present data identifies DAT as another inter-
action partner of the CaMKIIa association domain, link-
ing the binding of CaMKIIa to DAT with the neurobiology
of AMPH.
Experimental Procedures
Yeast Two-Hybrid Screen
The yeast two-hybrid screen was performed using the HybridHunter
system (Invitrogen) as described in the Supplemental Data. The 46
C-terminal residues of the human DAT (hDAT) were used as bait
against a human brain cDNA library.
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The GST fusion proteins containing positions 597–620 (C24), 575–
620 (C46), 581–620 (C40), and 581–609 (C40del11) of the hDAT and
positions 594–617 of NET and 607–630 of SERT were generated as
described in the Supplemental Data. For stable or transient expres-
sion of the hDAT, we used either synDAT (a synthetic human DAT
gene) in pcDNA3 (Loland et al., 2004), synDAT with an N-terminal
FLAG tag in the bicistronic vector pCIN4, or synDAT tagged at the
N terminus with yellow fluorescent protein in the bicistronic vector
pcHygro (Saunders et al., 2000). The hDAT constructs in which
Ser2, Ser4, Ser7, Ser12, and Ser13 were mutated to alanines (S/A)
and aspartate (S/D) were generated as described (Khoshbouei
et al., 2004). See the Supplemental Data for details.
Cell Culture and Transfection
EM4 cells, HEK293 cells stably transfected with macrophage scav-
enger receptor to promote adherence, were grown as described
(Khoshbouei et al., 2004). T-Rex HEK293 cells (human embryonic
kidney) (Invitrogen) with stable expression of Tet repressor from
pcDNA6/TR were grown as EM4 cells except that 5 mg/ml blasticidin
and 175 mg/ml hygromycin were added to the media. Transfections
were performed with the Lipofectamine 2000 transfection kit
(Invitrogen).
Neuronal Cultures
Postnatally derived rat midbrain dopaminergic neurons were iso-
lated and grown as described in the Supplemental Data, modified
from Rayport et al. (1992). Mouse midbrain dopaminergic neurons
were prepared as described in the Supplemental Data.
In Vitro Binding Assays
Purified murine CaMKIIa was autophosphorylated in the presence
of 2 mM calmodulin and [32P]-g-ATP (Amersham Biosciences) and
incubated with hDAT, hNET, or hSERT GST fusion proteins on gluta-
thione beads for 30 min at 37C. The beads were washed with
ice-cold TBS with 0.1% Triton X-100 before elution and detection
of binding by SDS-PAGE and autoradiography. For detection of
binding to CaMKIIa expressed in cells, lysates from CaMKIIa T-
Rex HEK293 cells induced with tetracycline were incubated with
DAT GST fusion proteins as indicated. The beads were washed be-
fore elution and analysis by SDS-PAGE/immunoblotting. For detec-
tion of binding to endogenously expressed CaMKIIa, crude PSDs
from rat brains were prepared (Gardoni et al., 1999). PSDs were sol-
ubilized in TBS with 0.1% SDS, diluted in TBS, and incubated with
hDAT GST fusion proteins. The beads were washed before elution
and analysis by SDS-PAGE/immunoblotting. See the Supplemental
Data for details.
Immunoprecipitations
Lysates from T-Rex HEK293 CaMKIIa cells, stably or transiently ex-
pressing hDAT or c-myc-tagged hSERT (prepared in TBS containing
1% [v/v] Triton X-100, 5 mM N-ethylmaleimide, 200 mM PMSF, and
a protease inhibitor cocktail [Roche Diagnostics]) were incubated
with either 1 ml rat MAB369 DAT antibody or 1 ml goat CaMKIIa anti-
body for 1 hr at 4C. Formed complexes were isolated with Protein G
agarose followed by SDS-PAGE and immunoblotting. See the Sup-
plemental Data for details.
Immunocytochemistry and Confocal Microscopy
Immunostaining was performed as described (Bjerggaard et al.,
2004). Dopaminergic neurons were fixed in 4% formaldehyde and
blocked/permeabilized with blocking-permeabilizing solution (5%
goat serum, 1% BSA, and 0.1% saponin in PBS buffer) followed
by incubation with indicated primary antibodies (MAB369 rat anti-
DAT antibody [Chemicon, Temecula, CA] 1:1000; rabbit anti-CaMKII
[Santa Cruz] 1:300; rabbit anti VMAT2 [Pel-Freez Biologicals] 1:2000;
rabbit anti-tyrosine hydroxylase [Affinity Bioreagents] 1:1000). Sec-
ondary antibodies used included goat anti-rat Alexa Fluor 488
(1:1000) and goat anti-rabbit Alexa Fluor 568 (Molecular Probes).
Stained cells were visualized using a Zeiss LSM 510 confocal laser
scanning microscope with an oil-immersion 633 objective.In Vitro Phosphorylation
Indicated protein kinases (50 ng) were incubated with 50mM of a pep-
tide corresponding to the first 27 residues of hDAT (NH2- MSK SKC
SVG LMS SVV APA KEP NAV GPK RR amide) or the indicated con-
centrations of the appropriate positive control substrates in the pres-
ence of 10 mM Mg2+ and 0.1 mM [g32P]ATP for 10 min at 30C. Re-
combinant CaMKIIa (Calbiochem) was incubated in the presence
of 0.4 mM CaCl2 and 0.1 mg/ml calmodulin. After the incubation
the mixture was filtered, washed, and counted for incorporated
32P. Note that the peptide contained two additional Arg residues at
the C terminus to facilitate its binding to the negatively charged filter.
All kinases (except CaMKIIa) were obtained from the Department of
Signal Transduction Therapy, University of Dundee. Phosphorylation
of the N-terminal peptide was compared with that of the appropriate
control substrates for each kinase, which included 30 mM phospho
glycogen synthase (GSK3), 30 mM kemptide (LRRASLG) (PKA),
30 mM crosstide (GRPRTSSFAEG) (p70S6K), 50 mM autocamtide 2
(KKALRRQETVDAL-amide) (CaMKII), 0.2 mg/ml histone H1 (PKC
and cdc2), and a coupled MAPK kinase assay (MEK1).
Amperometry/Electrophysiology
Whole-cell and amperometric currents were recorded as described
previously (Khoshbouei et al., 2004) in EM4 cells expressing YFP-
hDAT, YFP-hDAT S/A, and YFP-hDAT S/D or in midbrain dopaminer-
gic neuron. When noted, purified monomeric CaMKIIa (residues 1–
380), which was thiophosphorylated at Thr286 to be constitutively
active and resistant to phosphatases, was added to the internal so-
lution. In control experiments, an equal amount of heat-inactivated
(treated at 70C for 20 min) monomeric CaMKIIa was added. See
the Supplemental Data for details.
Efflux Experiments
Efflux experiments were performed in a superfusion system as de-
scribed using [3H]MPP+ as radioactive substrate (Pifl and Singer,
1999; Scholze et al., 2002; Sitte et al., 1998). Efflux in striatal slices
was performed essentially as described by Scholze et al. (Scholze
et al., 2002) except that the experiments were performed without
EDTA in the superfusion buffer. See the Supplemental Data for
details.
In Vivo High-Speed Chronoamperometry
In vivo high-speed chronoamperometry was perfomed as described
(Callaghan et al., 2005; Daws et al., 2000; Montanez et al., 2003) on
male C57BL/6J mice at 8–10 weeks of age. The electrochemical re-
cording assembly consisted of a Nafion-coated, single carbon fiber
electrode attached to a double-barrel micropipette filled with either
AMPH (800 mM, Sigma), KN93 (400 mM Calbiochem), or aCSF vehicle
(pH 7.4). KN93 did not itself produce an electrochemical signal
in vitro. The electrode-micropipette recording assembly was low-
ered into the dorsal striatum of anesthetized mice before high-speed
chronoamperometric recordings were made. AMPH (125 nl, 100
pmol) was applied into the striatum by pressure-ejection (5–25 psi
for 0.25–3.0 s) to evoke release of endogenous DA. As soon as the
DA was cleared from extracellular fluid (ECF), typically 5–30 min after
AMPH-application, KN93 (125 nl, 50 pmol) or aCSF (125 nl) was lo-
cally applied to striatum (5–25 psi for 0.25–3.0 s), and 45 min and
90 min later the same amount of AMPH was again pressure-ejected.
The placement of the electrode tip was verified histologically.
AMPH-evoked DA efflux was analyzed using one-way analysis of
variance (ANOVA) followed by Tukey’s post hoc tests.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/51/4/417/DC1/.
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